CLA Stock Overview A clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Akari Therapeutics, Plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Akari Therapeutics Historical stock prices Current Share Price US$1.17 52 Week High US$3.90 52 Week Low US$0.83 Beta 0.79 1 Month Change 34.48% 3 Month Change -50.00% 1 Year Change -54.30% 3 Year Change -95.24% 5 Year Change -96.52% Change since IPO -99.64%
Recent News & Updates Akari Therapeutics, Plc Announces Board Changes
Akari Therapeutics, Plc Appoints Torsten Hombeck as Chief Financial Officer Dec 16 Wendy Dicicco No Longer Serve as Interim Chief Financial Officer of Akari Therapeutics, Plc
Akari Therapeutics, Plc announced delayed 10-Q filing Nov 16 Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.
Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement Oct 05 See more updates Akari Therapeutics, Plc Announces Board Changes
Akari Therapeutics, Plc Appoints Torsten Hombeck as Chief Financial Officer Dec 16 Wendy Dicicco No Longer Serve as Interim Chief Financial Officer of Akari Therapeutics, Plc
Akari Therapeutics, Plc announced delayed 10-Q filing Nov 16 Akari Therapeutics, Plc (NasdaqCM:AKTX) completed the acquisition of Peak Bio, Inc. (OTCPK:PKBO) from Pranabio Investments, Llc and others.
Akari Therapeutics Receives Delisting Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension Granted by Nasdaq to Regain Compliance with the Stockholders’ Equity Requirement Oct 05
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy Aug 20 Akari Therapeutics, Plc announced delayed 10-Q filing Aug 16
Akari Therapeutics, plc Appoints Samir R. Patel as Interim President Jun 08
Akari Therapeutics, Plc, Annual General Meeting, Jun 27, 2024 Jun 06 Akari Therapeutics, Plc announced that it has received $0.5 million in funding May 18
New major risk - Financial position May 17 Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc
Akari Therapeutics Receives a Letter from the Listing Qualifications Staff of the Nasdaq Capital Market Apr 13
New major risk - Share price stability Apr 13
New major risk - Shareholder dilution Apr 07
New major risk - Market cap size Apr 02
New major risk - Negative shareholders equity Mar 31
Akari Therapeutics, Plc (NasdaqCM:AKTX) entered into a definitive agreement to acquire Peak Bio, Inc. (OTCPK:PKBO). Mar 06
Akari Therapeutics Appoints Samir R. Patel, M.D. to Board of Directors Dec 01 Akari Therapeutics, Plc announced that it expects to receive $2 million in funding Sep 22
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Sep 06
Akari Therapeutics, Plc Announces Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs, Effective September 1, 2023 Aug 04
Akari Therapeutics, plc Grants Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation Jul 28
Akari Therapeutics, plc Announces Appointment of Wendy Dicicco as Interim Chief Financial Officer Jul 22
Less than half of directors are independent Jul 16
Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA Jul 14
Akari Therapeutics, plc Announces Updates on the Development of Long-Acting Pas-Nomacopan as A Potential Treatment for Geographic Atrophy Jul 12
Akari Therapeutics, plc Announces Management Appointments Jul 06
Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2023 Jun 07
Akari Therapeutics, Plc Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy Feb 16
Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric Hsct-Tma into Pivotal Part B and Addition of A New Pipeline Program Developing Nomacopan for Hsct-Tma in Adults Feb 14
No longer forecast to breakeven Dec 07
Insufficient new directors Nov 16
Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of nomacopan for the Treatment of Pediatric HSCT-TMA Nov 11
Akari Therapeutics Announces the Appointment of John F. Neylan, III as Executive Vice President, Chief Medical Officer Nov 09
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification Oct 31
Akari Therapeutics, plc Announces That It Is Prioritizing Two Pipeline Programs Aug 03
Insufficient new directors Jul 29
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy Jul 29
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase Iii Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy Jul 08
Akari Therapeutics, Plc Appoints Melissa Bradford-Klug as Chief Operating Officer, Effective July 1, 2022 Jun 14
Akari Therapeutics, Plc, Annual General Meeting, Jun 30, 2022 Jun 08
Akari Therapeutics, Plc Presents Results from the CASCADE and CORONET Studies in COVID-19 May 20
Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology May 12 Akari Therapeutics, Plc Presents Positive Results from Two Preclinical Studies of Its Lead Asset, Investigational Nomacopan May 10
Insufficient new directors Apr 27 Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors Akari Therapeutics, Plc Appoints Rachelle Jacques as President and Join its Board of Directors
Akari Therapeutics, plc Announces New Data Showing That Clinical Outcomes in U.S. Army Trauma Patients Correlate with Complement Activation Mar 01
Akari Therapeutics, plc Announces Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases Jan 27
Akari Therapeutics, Plc announces FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies Jan 20
Akari Therapeutics, Plc Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders Dec 03
Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid Apr 29
Akari Therapeutics, Plc Announces a Cooperative Research and Development Agreement with the U.S. Army Institute of Surgical Research for Nomacopan in Trauma Mar 05
Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis Feb 26
New 90-day high: €3.12 Feb 23
Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to Treat Neuropathic Pain and Dermatological Disease Feb 02
New 90-day high: €2.00 Jan 16
Akari Therapeutics, Plc Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Dec 13
New 90-day high: €1.63 Dec 09
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease Dec 04
New 90-day low: €1.19 Nov 03
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia Oct 07
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid Oct 04
New 90-day low - €1.30 Sep 05
New 90-day low - €1.50 Aug 15 Shareholder Returns CLA DE Biotechs DE Market 7D 6.4% 5.5% 1.2% 1Y -54.3% -3.7% 10.1%
See full shareholder returns
Return vs Market: CLA underperformed the German Market which returned 10.1% over the past year.
Price Volatility Is CLA's price volatile compared to industry and market? CLA volatility CLA Average Weekly Movement 20.4% Biotechs Industry Average Movement 7.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: CLA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CLA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
Show more Akari Therapeutics, Plc Fundamentals Summary How do Akari Therapeutics's earnings and revenue compare to its market cap? CLA fundamental statistics Market cap €30.93m Earnings (TTM ) -€19.68m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CLA income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$20.16m Earnings -US$20.16m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.81 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -14.9%
How did CLA perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 00:41 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Akari Therapeutics, Plc is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Madhu Kumar B. Riley Securities, Inc. Arlinda Lee Canaccord Genuity
Show 2 more analysts 
